STAT

Listen: Pharma’s future in China, CRISPR meets Netflix, & where VC dollars come from

Should drug companies be free-speech advocates? Is your retirement dependent on CRISPR? And how useful is a glow-in-the-dark dog? All that and more on the new episode of "The Readout…

Should drug companies be free-speech advocates? Is your retirement dependent on CRISPR? And how useful is a glow-in-the-dark dog?

We discuss all

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks